Share this via
HCL Technologies reported a 9.7% drop in net profit for Q1 FY26, reaching Rs 3,843 crore, influenced by increased expenses and a client bankruptcy. Despite this, revenue rose 8.1% to Rs 30,349 crore, driven by technology and services. HCLTech has raised its FY26 revenue growth outlook to 3–5%, citing stable demand and anticipated stronger deal bookings.
As a part of agreement, Incyte has granted to Sun a limited, non-exclusive license to U.S. Patent and certainother related patents with respect to oral deuruxolitinib for certain agreed-upon non-hematology-oncology indications including alopecia areata, in the U.S.
Get over your FOMO of knowing what's happening. Never miss what matters to you!
